Cost-Effectiveness Analysis of RFVIIIFc Versus Contemporary RFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States

Overview

Journal Pharmacoecon Open

Date 2021 Jul 16

PMID 34268704

Citations 1

Authors

Ash Bullement

Emma S Knowles

Pronabesh DasMahapatra

Talaha Ali

Ron Preblick

Affiliations

Soon will be listed here.

Abstract

Background: A range of treatments for patients with severe hemophilia A (HA) have been developed over the last decade, allowing for reduced frequency of administration and improved outcomes (joint health and breakthrough bleeding rates). While clinically effective, the cost effectiveness of these treatments has not been established.

Objective: This study presents a cost-effectiveness analysis of contemporary rFVIII treatments for severe HA patients without inhibitors.

Methods: A published semi-Markov model was used to compare three different prophylaxis regimens: (1) extended half-life (EHL) recombinant Factor VIII (rFVIII) Fc-fusion protein (rFVIIIFc, Eloctate, Sanofi), (2) EHL PEGylated rFVIII (PEG-rFVIII, Adynovate, Takeda), and (3) standard half-life (SHL) rFVIII (antihemophilic factor [recombinant], Advate, Takeda), used as a proxy for all SHL rFVIII treatments. Acquisition costs were included based on published dosing and weight data. Benefits were incorporated through published annualized bleeding rates, rates of target joint development/resolution, and improvements in the modified hemophilia joint health score. Results were presented as total, discounted costs, and quality-adjusted life-years (QALYs).

Results: rFVIIIFc was shown to provide the most QALYs (27.922) compared with both PEG-rFVIII (27.454) and SHL rFVIII (27.071), at lower costs. Discounted lifetime costs were estimated at US$18.235m (rFVIIIFc), US$20.198m (PEG-rFVIII), and US$18.285m (SHL rFVIII), and were predominantly affected by model settings related to acquisition costs, patient weight, and dosing.

Conclusions: rFVIIIFc may offer a cost-effective option for severe HA patients. Uncertainties owing to the limited evidence base is the main limitation of the study.

Citing Articles

Efmoroctocog Alfa: A Review in Haemophilia A.

Frampton J Drugs. 2021; 81(17):2035-2046.

PMID: 34743314 PMC: 8636404. DOI: 10.1007/s40265-021-01615-w.

References

Valentino L, Mamonov V, Hellmann A, Quon D, Chybicka A, Schroth P . A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012; 10(3):359-67. PMC: 3488301. DOI: 10.1111/j.1538-7836.2011.04611.x. View

Srivastava A, Brewer A, Mauser-Bunschoten E, Key N, Kitchen S, Llinas A . Guidelines for the management of hemophilia. Haemophilia. 2012; 19(1):e1-47. DOI: 10.1111/j.1365-2516.2012.02909.x. View

Nolan B, Mahlangu J, Pabinger I, Young G, Konkle B, Barnes C . Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020; 26(3):494-502. PMC: 7384031. DOI: 10.1111/hae.13953. View

Henry N, Jovanovic J, Schlueter M, Kritikou P, Wilson K, Myren K . Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. J Med Econ. 2017; 21(4):318-325. DOI: 10.1080/13696998.2017.1405816. View

Knobe K, Berntorp E . Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb. 2017; 1:51-59. PMC: 5556421. DOI: 10.15256/joc.2011.1.2. View

Cook K, Forbes S, Adamski K, Ma J, Chawla A, Garrison Jr L . Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ. 2020; 23(5):501-512. DOI: 10.1080/13696998.2020.1721508. View

Croteau S, Cheng D, Cohen A, Holmes C, Malec L, Silvey M . Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019; 25(4):668-675. DOI: 10.1111/hae.13758. View

Kuijlaars I, Timmer M, de Kleijn P, Pisters M, Fischer K . Monitoring joint health in haemophilia: Factors associated with deterioration. Haemophilia. 2017; 23(6):934-940. DOI: 10.1111/hae.13327. View

Konkle B, Skinner M, Iorio A . Hemophilia trials in the twenty-first century: Defining patient important outcomes. Res Pract Thromb Haemost. 2019; 3(2):184-192. PMC: 6462740. DOI: 10.1002/rth2.12195. View

10.

Bullement A, McMordie S, Hatswell A, Li N, Wilson K . Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data. Pharmacoecon Open. 2019; 4(1):133-142. PMC: 7018914. DOI: 10.1007/s41669-019-0158-8. View

11.

Konkle B, Stasyshyn O, Chowdary P, Bevan D, Mant T, Shima M . Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015; 126(9):1078-85. PMC: 4551361. DOI: 10.1182/blood-2015-03-630897. View

12.

Rodriguez-Merchan E . Articular Bleeding in Hemophilia. Cardiovasc Hematol Disord Drug Targets. 2017; 16(1):21-24. DOI: 10.2174/1871529x16666160613114506. View

13.

OHara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C . The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018; 16(1):84. PMC: 5932770. DOI: 10.1186/s12955-018-0908-9. View

14.

Mahlangu J, Powell J, Ragni M, Chowdary P, Josephson N, Pabinger I . Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2013; 123(3):317-25. PMC: 3894491. DOI: 10.1182/blood-2013-10-529974. View

15.

Puthenveetil G, Nugent D . Hemophilia - Impact of Recent Advances on Management. Indian J Pediatr. 2019; 87(2):134-140. DOI: 10.1007/s12098-019-03062-8. View

16.

Oldenburg J, Kulkarni R, Srivastava A, Mahlangu J, Blanchette V, Tsao E . Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2017; 24(1):77-84. DOI: 10.1111/hae.13353. View

17.

Soucie J, Wang C, Siddiqi A, Kulkarni R, Recht M, Konkle B . The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia. 2011; 17(2):196-203. DOI: 10.1111/j.1365-2516.2010.02400.x. View

18.

Neufeld E, Recht M, Sabio H, Saxena K, Solem C, Pickard A . Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value Health. 2012; 15(6):916-25. DOI: 10.1016/j.jval.2012.05.005. View

19.

Panicker J, Warrier I, Thomas R, Lusher J . The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia. 2003; 9(3):272-8. DOI: 10.1046/j.1365-2516.2003.00757.x. View

20.

Blanchette V, Shapiro A, Liesner R, Hernandez Navarro F, Warrier I, Schroth P . Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008; 6(8):1319-26. DOI: 10.1111/j.1538-7836.2008.03032.x. View